infantile jaundice

Rejected: After paying $80M to acquire it, Mallinckrodt’s jaundice drug snubbed by FDA’s advisory committee
Endpoints
Thu, 05/3/18 - 11:09 pm
Mallinckrodt
FDA
advisory panels
infantile jaundice
InfaCare
stannsoporfin
Mallinckrodt bags late-stage infantile jaundice drug in $425M InfaCare buyout deal
Endpoints
Mon, 08/7/17 - 11:25 am
Mallinckrodt
infantile jaundice
InfaCare
M&A
Stanate